Janssen Pharmaceuticals’ Carvykti™ (ciltacabtagene autoleucel; cilta-cel) is FDA approved to treat relapsed or refractory multiple myeloma in adults who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

• Carvykti is a chimeric antigen receptor T-cell (CAR-T) therapy created using the patient’s own immune cells. T-cells are collected from the patient and modified in a lab to specifically target multiple myeloma cells, then infused back into the patient.
• A one-time intravenous treatment, Carvykti must be given at a certified healthcare
• The product has launched at a wholesale acquisition cost (WAC) of $465,000.